146 related articles for article (PubMed ID: 6385028)
1. Results and follow-up of bladder tumors following transurethral resection.
Gibbons RP
Prog Clin Biol Res; 1984; 162A():359-73. PubMed ID: 6385028
[No Abstract] [Full Text] [Related]
2. Management of superficial bladder carcinoma with BCG. Long term follow-up.
Martínez-Piñeiro JA
Prog Clin Biol Res; 1984; 162B():335-45. PubMed ID: 6438642
[No Abstract] [Full Text] [Related]
3. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Herr HW
J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.
Jancke G; Damm O; Rosell J; Jahnson S
Scand J Urol Nephrol; 2008; 42(5):417-21. PubMed ID: 18609266
[TBL] [Abstract][Full Text] [Related]
5. [The preventive recurrent results of postoperative intravesical instillation therapy in bladder cancer].
Zhang S; Li H; Cheng H
Zhonghua Wai Ke Za Zhi; 1995 May; 33(5):304-6. PubMed ID: 7587700
[TBL] [Abstract][Full Text] [Related]
6. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
Fujimoto K; Chihara Y; Kondo H; Hirao Y
Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
[TBL] [Abstract][Full Text] [Related]
7. Resume of selected studies of the National Bladder Cancer Collaborative Group A and new protocols.
Prout GR; Kopp J
Prog Clin Biol Res; 1984; 162B():397-427. PubMed ID: 6438644
[No Abstract] [Full Text] [Related]
8. [Treatment of stage Ta,T1 and Tis bladder tumors using Calmette-Guérin bacillus vaccine].
Bretheau D; Lechevallier E; Rossi D; Albert P; de Fromont M; Coulange C
Prog Urol; 1993; 3(4):608-17. PubMed ID: 8401621
[TBL] [Abstract][Full Text] [Related]
9. Chemoimmune prophylaxis of superficial bladder carcinoma with cyclophosphamide and BCG.
Jaeger N; Adolphs HD; Vahlensieck W
Prog Clin Biol Res; 1989; 303():393-9. PubMed ID: 2780655
[No Abstract] [Full Text] [Related]
10. [Our experience in treating patients with surface cancer of the bladder].
Matveev BP; Figurin KM; Romanov VA; Cheban NL
Urol Nefrol (Mosk); 1995; (5):35-8. PubMed ID: 8571484
[TBL] [Abstract][Full Text] [Related]
11. Does the management of bladder perforation during transurethral resection of superficial bladder tumors predispose to extravesical tumor recurrence?
Skolarikos A; Chrisofos M; Ferakis N; Papatsoris A; Dellis A; Deliveliotis C
J Urol; 2005 Jun; 173(6):1908-11. PubMed ID: 15879773
[TBL] [Abstract][Full Text] [Related]
12. Bladder-sparing therapy for muscle-infiltrating bladder cancer.
Pansadoro V; Emiliozzi P
Nat Clin Pract Urol; 2008 Jul; 5(7):368-75. PubMed ID: 18560383
[TBL] [Abstract][Full Text] [Related]
13. [BCG immunotherapy in the treatment of superficial bladder tumors].
Samodai L; Drinóczy M; Kolozsy Z; Mohácsi L; Dauda G; Porkoláb Z
Orv Hetil; 1986 Oct; 127(40):2441-6. PubMed ID: 3537907
[No Abstract] [Full Text] [Related]
14. Carcinoma in situ of the bladder.
Herr HW
Semin Urol; 1983 Feb; 1(1):15-22. PubMed ID: 6679095
[No Abstract] [Full Text] [Related]
15. Re: Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Palou J; Rodríguez O; Segarra J; Rosales A
J Urol; 2006 Jul; 176(1):407; author reply 407-8. PubMed ID: 16753451
[No Abstract] [Full Text] [Related]
16. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
17. Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder.
Zhang GK; Uke ET; Sharer WC; Borkon WD; Bernstein SM
J Urol; 1996 Jun; 155(6):1907-9. PubMed ID: 8618284
[TBL] [Abstract][Full Text] [Related]
18. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy.
Weiss C; Wittlinger M; Engehausen DG; Krause FS; Ott OJ; Dunst J; Sauer R; Rödel C
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1502-6. PubMed ID: 17935905
[TBL] [Abstract][Full Text] [Related]
19. [Combined therapy of bladder cancer].
Benchev V; Pavlov P
Khirurgiia (Sofiia); 1985; 38(1):23-6. PubMed ID: 4040989
[No Abstract] [Full Text] [Related]
20. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.
Hata M; Miyanaga N; Tokuuye K; Saida Y; Ohara K; Sugahara S; Kagei K; Igaki H; Hashimoto T; Hattori K; Shimazui T; Akaza H; Akine Y
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1371-9. PubMed ID: 16580495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
